[1]
|
Leem, E. and Kim, S.R. (2020) Limited Therapeutic Potential of Astrocyte Elevated Gene-1 Transduction in an Animal Model of Parkinson’s Disease. Neural Regeneration Research, 15, 1850-1851.
https://doi.org/10.4103/1673-5374.280315
|
[2]
|
Schrag, A. (2018) Testing the MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders, 33, 1518-1520. https://doi.org/10.1002/mds.27543
|
[3]
|
Villacé, P., Mella, R.M. and Kortazar, D. (2017) Mitochondria in the Context of Parkinson’s Disease. Neural Regeneration Research, 12, 214-215. https://doi.org/10.4103/1673-5374.200802
|
[4]
|
Shen, B., Lin, Y., Bi, C., et al. (2019) Translational Informatics for Parkinson’s Disease: From Big Biomedical Data to Small Actionable Alterations. Genomics Proteomics Bioinformatics, 17, 415-429.
https://doi.org/10.1016/j.gpb.2018.10.007
|
[5]
|
Raza, C., Anjum, R. and Shakeel, N. (2019) Parkinson’s Disease: Mechanisms, Translational Models and Management Strategies. Life Science, 226, 77-90. https://doi.org/10.1016/j.lfs.2019.03.057
|
[6]
|
Roheger, M., Kalbe, E. and Liepelt-Scarfone, I. (2018) Progression of Cognitive Decline in Parkinson’s Disease. Parkinson’s Disease, 8, 183-193. https://doi.org/10.3233/JPD-181306
|
[7]
|
Liu, J.Q., Zhao, M., Zhang, Z., et al. (2020) Rg1 Improves LPS-Induced Parkinsonian Symptoms in Mice via Inhibition of NF-κB Signaling and Modulation of M1/M2 Polarization. Acta Phar-macologica Sinica, 41, 523-534.
https://doi.org/10.1038/s41401-020-0358-x
|
[8]
|
Hertz, N.T., Berthet, A., Sos, M.L., et al. (2013) A Neo-Substrate That Amplifies Catalytic Activity of Parkinson’s—Disease-Related Kinase PINK1. Cell, 154, 737-747. https://doi.org/10.1016/j.cell.2013.07.030
|
[9]
|
王雪晶, 郭纪锋, 江泓, 等. 帕金森病相关蛋白Parkin与PINK1的相互作用研究[J]. 生物化学与生物物理进展, 2010, 37(9): 983-987.
|
[10]
|
李婷, 陈靖茹, 陆佳宁, 等. 帕金森病非运动症状研究进展[J]. 新中医, 2019, 51(6): 37-39.
|
[11]
|
Pablo, M., Anthony, H.V., Stocchi, F., et al. (2007) Prev-alence of Nonmotor Symptoms in Parkinson’s Disease in an International Srtting: Study Using Nonmotor Symptoms Questionnaire in 545 Patients. Movement Disorders, 22, 1623-1629. https://doi.org/10.1002/mds.21586
|
[12]
|
Jagger, C., Andersen, K., Breteler, M.M., et al. (2000) Prognosis with Dementia in Europe: A Collaborative Study of Population-Based Cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54, S16-S20.
|
[13]
|
Armstrong, M.J. and Okun, M.S. (2020) Diagnosis and Treatment of Parkinson Disease: A Review. The Journal of the American Medical Association, 323, 548-560. https://doi.org/10.1001/jama.2019.22360
|
[14]
|
Dauer, W. and Przedborski, S. (2003) Parkinson’s Disease: Mecha-nisms and Models. Neuron, 39, 889-909.
https://doi.org/10.1016/S0896-6273(03)00568-3
|
[15]
|
Lu, B., Nagappan, G. and Lu, Y. (2014) BDNF and Synaptic Plasticity, Cognitive Function, and Dysfunction. Handbook of Experimental Pharmacology, 220, 223-250. https://doi.org/10.1007/978-3-642-45106-5_9
|
[16]
|
Guidi, M., Muiños-Gimeno, M., Kagerbauer, B., et al. (2010) Overexpression of miR-128 Specifically Inhibits the Truncated Isoform of NTRK3 and Upregulates BCL2 in SH-SY5Y Neuroblastoma Cells. BMC Molecular Biology, 11, 95. https://doi.org/10.1186/1471-2199-11-95
|
[17]
|
Beltaifa, S., Webster, M.J., Ligons, D.L., et al. (2005) Discordant Changes in Cortical TrkC mRNA and Protein during the Human Lifespan. European Journal of Neuroscience, 21, 2433-2444.
https://doi.org/10.1111/j.1460-9568.2005.04074.x
|
[18]
|
Chu, H.Y. (2020) Synaptic and Cellular Plasticity in Par-kinson’s Disease. Acta Pharmacologica Sinica, 41, 447-452.
https://doi.org/10.1038/s41401-020-0371-0
|
[19]
|
Esteban, P.F., Yoon, H.Y., Becker, J., et al. (2006) A Ki-nase-Deficient TrkC Receptor Isoform Activates Arf6-Rac1 Signaling through the Scaffold Protein Tamalin. Cell Biology, 173, 291-299. https://doi.org/10.1083/jcb.200512013
|
[20]
|
Dmitrieva, V.G., Stavchansky, V.V., Povarova, O.V., et al. (2016) Effects of Ischemia on the Expression of Neurotrophins and Their Receptors in Rat Brain Structures outside the Lesion Site, Including on the Opposite Hemisphere. Molecular Biology, 50, 775-784. https://doi.org/10.1134/S0026893316030067
|
[21]
|
Brown, D.T., Vickers, J.C., Stuart, K.E., et al. (2020) The BDNF Val66Met Polymorphism Modulates Resilience of Neurological Functioning to Brain Ageing and Dementia: A Narrative Review. Brain Sciences, 10, E195.
https://doi.org/10.3390/brainsci10040195
|
[22]
|
Bahiraee, A. and Ebrahimi, R. (2018) A Noble Pathological Role for Alpha-Synuclein in Triggering Neurodegeneration of Parkinson’s Disease. Movement Disorders, 33, 404. https://doi.org/10.1002/mds.27306
|
[23]
|
Baquet, Z.C., Bickford, P.C. and Jones, K.R. (2005) Brain-Derived Neu-rotrophic Factor Is Required for the Establishment of the Proper Number of Dopaminergic Neurons in the Substantia Nigra Pars Compacta. NeuroSci, 25, 6251- 6259. https://doi.org/10.1523/JNEUROSCI.4601-04.2005
|
[24]
|
Ji, R., Smith, M., Niimi, Y., et al. (2019) Focused Ultrasound Enhanced Intranasal Delivery of Brain Derived Neurotrophic Factor Produces Neurorestorative Effects in a Parkinson’s Disease Mouse Model. Scientific Reports, 9, Article No. 19402. https://doi.org/10.1038/s41598-019-55294-5
|
[25]
|
Kasanga, E.A., Owens, C.L., Salvatore, M.F., et al. (2019) GFR-α1 Expression in Substantia Nigra Increases Bilaterally Following Unilateral Striatal GDNF in Aged Rats and Attenuates Nigral Tyrosine Hydroxylase Loss Following 6-OHDA Nigrostriatal Lesion. ACS Chemical Neurosci-ence, 10, 4237-4249.
https://doi.org/10.1021/acschemneuro.9b00291
|
[26]
|
Crowder, R.J., Enomoto, H., Yang, M., et al. (2004) Dok-6, a Novel p62 Dok Family Member, Promotes Ret-Mediated Neurite Outgrowth. Journal of Biological Chemistry, 279, 42072-42081. https://doi.org/10.1074/jbc.M403726200
|
[27]
|
Hegarty, S.V., Wyatt, L., Howard, L., et al. (2017) Zeb2 Is a Negative Regulator of Midbrain Dopaminergic Axon Growth and Target Innervation. Scientific Reports, 7, Ar-ticle No. 8568. https://doi.org/10.1038/s41598-017-08900-3
|
[28]
|
Stojkovska, I., Krainc, D. and Mazzulli, J.R. (2018) Molecular Mechanisms of α-Synuclein and GBA1 in Parkinson’s Disease. Cell and Tissue Research, 373, 51-60. https://doi.org/10.1007/s00441-017-2704-y
|
[29]
|
Aflaki, E., Borger, D.K., Moaven, N., et al. (2016) A New Glu-cocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. NeuroSci, 36, 7441-7452. https://doi.org/10.1523/JNEUROSCI.0636-16.2016
|